These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25467091)

  • 21. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
    Manosroi W; Phimphilai M; Waisayanand N; Buranapin S; Deerochanawong C; Gunaparn S; Phrommintikul A; Wongcharoen W;
    J Diabetes Investig; 2023 Dec; 14(12):1391-1400. PubMed ID: 37610280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
    Menon V; Kumar A; Patel DR; John JS; Wolski KE; McErlean E; Riesmeyer JS; Weerakkody G; Ruotolo G; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    J Am Heart Assoc; 2020 Jan; 9(1):e014328. PubMed ID: 31852422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children.
    Takaya J; Tanabe Y; Kuroyanagi Y; Kaneko K
    Endocr J; 2015; 62(6):551-6. PubMed ID: 25903645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.
    Wilson AM; Shin DS; Weatherby C; Harada RK; Ng MK; Nair N; Kielstein J; Cooke JP
    Vasc Med; 2010 Aug; 15(4):267-74. PubMed ID: 20484311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
    Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
    Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes.
    Krzyzanowska K; Mittermayer F; Krugluger W; Schnack C; Hofer M; Wolzt M; Schernthaner G
    Atherosclerosis; 2006 Nov; 189(1):236-40. PubMed ID: 16414052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.
    Böger RH; Sullivan LM; Schwedhelm E; Wang TJ; Maas R; Benjamin EJ; Schulze F; Xanthakis V; Benndorf RA; Vasan RS
    Circulation; 2009 Mar; 119(12):1592-600. PubMed ID: 19289633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
    Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
    Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.
    Chao TF; Lu TM; Lin YJ; Tsao HM; Chang SL; Lo LW; Hu YF; Tuan TC; Hsieh MH; Chen SA
    PLoS One; 2013; 8(8):e71675. PubMed ID: 23951217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.
    Bots SH; van der Graaf Y; Nathoe HM; de Borst GJ; Kappelle JL; Visseren FL; Westerink J;
    Cardiovasc Diabetol; 2016 Jul; 15(1):101. PubMed ID: 27431507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
    Zobel EH; von Scholten BJ; Reinhard H; Persson F; Teerlink T; Hansen TW; Parving HH; Jacobsen PK; Rossing P
    Cardiovasc Diabetol; 2017 Jul; 16(1):88. PubMed ID: 28697799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.
    Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Pinsky DJ; Marmur JD
    Coron Artery Dis; 2009 Mar; 20(2):112-7. PubMed ID: 19240644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients.
    Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI
    Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The value of serum asymmetric dimethylarginine levels for the determination of masked hypertension in patients with diabetes mellitus.
    Taner A; Unlu A; Kayrak M; Tekinalp M; Ayhan SS; Arıbaş A; Erdem SS
    Atherosclerosis; 2013 Jun; 228(2):432-7. PubMed ID: 23540293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study.
    Surdacki A; Kruszelnicka O; Rakowski T; Jaźwińska-Kozuba A; Dubiel JS
    Cardiovasc Diabetol; 2013; 12():64. PubMed ID: 23578341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease.
    Kranenburg G; van der Graaf Y; van der Leeuw J; Nathoe HM; de Borst GJ; Kappelle LJ; Visseren FL; Westerink J;
    Diabetes Care; 2015 Oct; 38(10):1930-6. PubMed ID: 26307606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion.
    Sen N; Ozlu MF; Akgul EO; Kanat S; Cayci T; Turak O; Yaman H; Sokmen E; Ozcan F; Maden O; Demir AD; Covic A; Kanbay M
    Atherosclerosis; 2011 Nov; 219(1):304-10. PubMed ID: 21726864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethylarginines in patients with type 2 diabetes mellitus: relation with the glycaemic control.
    Can A; Bekpinar S; Gurdol F; Tutuncu Y; Unlucerci Y; Dinccag N
    Diabetes Res Clin Pract; 2011 Dec; 94(3):e61-4. PubMed ID: 21889812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin A
    She J; Deng Y; Wu Y; Xia Y; Li H; Liang X; Shi R; Yuan Z
    Cardiovasc Diabetol; 2017 Aug; 16(1):97. PubMed ID: 28789650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ADMA is a correlate of insulin resistance in early-stage diabetes independent of hs-CRP and body adiposity.
    Nakhjavani M; Karimi-Jafari H; Esteghamati A; Khalilzadeh O; Asgarani F; Ghadiri-Anari A
    Ann Endocrinol (Paris); 2010 Sep; 71(4):303-8. PubMed ID: 20434720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.